JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB32086

Anti-EGFR (phospho Y1086) 抗体 [Y39]

Anti-EGFR (phospho Y1086) antibody [Y39]

Be the first to review this product! Submit a review

|

(12 Publications)

Rabbit Recombinant Monoclonal EGFR phospho Y1086 antibody. Suitable for IP, Dot, WB, ICC/IF and reacts with Human, Synthetic peptide samples. Cited in 12 publications.

別名を表示する

ERBB, ERBB1, HER1, EGFR, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1

7 Images
Immunocytochemistry/ Immunofluorescence - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)

Immunofluorescent analysis of EGFR (phospho Y1086) expression in A431 cell culture, using 1/100 ab32086.

Immunocytochemistry/ Immunofluorescence - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)

Immunocytochemistry/ Immunofluorescence analysis of A431 (Human epidermoid carcinoma cell line) cells labeling EGFR (phospho Y1086) with ab32086 at 1/100 3 μg/ml. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% tritonX-100. ab150077 a AlexaFluor®488 Goat anti-Rabbit IgG was used as the secondary antibody at 1/1000 2 μg/ml. Cells were counterstained with ab195889 anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 2.5 μg/ml. Nuclear stain was DAPI (blue).

The green staining on the membrane was increased in the EGF (100ng/ml 10min) treated A431 cells when compared with A431 cells without treatment. After LP treatment the green signaling was obviously decreased.

For the pan antibody there was no great difference after EGF (100ng/ml 10min) or EGF (100ng/ml 10min) + LP treatment. The data showed mostly membranous staining.

Immunoprecipitation - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)
  • IP

Lab

Immunoprecipitation - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)

Purified ab32086 at 1/20 dilution (1μg) immunoprecipitating EGFR in A431 treated with 100ng/mL EGF for 30min whole cell lysate.
Lane 1 (input) : A431 (Human epidermoid carcinoma epithelial cell) treated with 100ng/mL EGF for 30min whole cell lysate 10μg
Lane 2 (+) : ab32086 + A431 treated with 100ng/mL EGF for 30min whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab32086 in A431 treated with 100ng/mL EGF for 30min whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 175 kDa

All lanes:

Immunoprecipitation - Anti-EGFR (phospho Y1086) antibody [Y39] (ab32086)

Predicted band size: 129 kDa,134 kDa

false

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)
  • WB

Lab

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)

Blocking and dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (ab32086) at 1/3000 dilution

Lane 1:

Untreated A431 (Human epidermoid carcinoma cell line) whole cell lysates at 15 µg

Lane 2:

A431 (Human epidermoid carcinoma cell line) treated with 100 ng/ml EGF for 10 minutes whole cell lysates at 15 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 134 kDa

Observed band size: 170 kDa

false

Exposure time: 10s

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)
  • WB

Unknown

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)

All lanes:

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (ab32086) at 1/10000 dilution

Lane 1:

Untreated A431 cell lysate

Lane 2:

A431 cell lysate, treated with EGF

Predicted band size: 134 kDa

Observed band size: 150 kDa

false

Dot Blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)
  • Dot

Unknown

Dot Blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)

Dot blot analysis of EGFR (phospho Y1086) phospho peptide (Lane 1) EGFR non-phospho peptide (Lane 2) labeling EGFR (phospho Y1086) with ab32068 at a dilution of 1/1000. Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated (ab97051) was used as the secondary antibody at a dilution of 1/100000.

Blocking and dilution buffer : 5% NFDM/TBST.

Exposure time : 5 seconds.

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)
  • WB

CiteAb

Western blot - Anti-EGFR (phospho Y1086) antibody [Y39] (AB32086)

EGFR (phospho Y1086) western blot using anti-EGFR (phospho Y1086) antibody [Y39] ab32086. Publication image and figure legend from Hashikawa, K. I., Katamune, C., et al., 2017, Sci Rep, PubMed 28855649.

ab32086 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab32086 please see the product overview.

Effects of p16INK4a on EGF receptor-mediated Ras activation in human keratinocytes. HaCaT cells were infected with retroviral vectors expressing Flag-tagged p16INK4a. (a) Protein levels of Flag-tagged p16INK4a, total Ras, and EGF receptor in HaCaT cells. Plus and minus indicate the infection with p16INK4a-Flag expressing vectors. Full-size images are presented in Supplementary Fig. 6. Data shown were confirmed in more than three independent experiments. (b) mRNA levels of inflammatory cytokines in cells infected or not infected with the p16INK4a-Flag expressing vectors. (Means ± s.e.m.; n = 6). **p < 0.01 significant difference control cells (t10 = -8.393, p < 0.001 for IL-6, t10 = -4.161, P = 0.002 for Ccl2, t10 = -3.975, P = 0.034 for Tnf-α; unpaired t-test, two-sided). (c) Protein levels of phosphorylated EGFR (right) and the amount of the active form of Ras (left) in cells infected or not infected with the p16INK4a-Flag expressing vectors. For right panel, western blot data were confirmed in three mice in each group. Full-size images are presented in Supplementary Fig. 7. For left panel, cells were incubated in serum-starved media for 24 hours and then stimulated with 200 ng/ml of EGF for 1 minute. Plus and minus indicate the introduction of the p16INK4a-Flag vector and the EGF treatment, respectively. Values of absorbance at 450 nm were obtained and normalized by total protein levels (Means ± s.e.m.; n = 4). *p < 0.05 significant difference between the two groups (F3,12 = 29.245, p < 0.001; ANOVA with Tukey-Kramer's post-hoc test).

false

関連する標識済み抗体及び組成の異なる製品 (1)

  • Carrier free

    Anti-EGFR (phospho Y1086) antibody [Y39] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

Y39

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

IP, WB, ICC/IF, Dot

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

特異性

This antibody only detects EGFR phosphorylated on Tyrosine 1086 of the mature human isoform 1.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "IHC" : {"fullname" : "Immunohistochemistry", "shortname":"IHC"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/150", "IP-species-notes": "<p></p>", "IHC-species-checked": "notRecommended", "IHC-species-dilution-info": "", "IHC-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100 - 1/250", "ICCIF-species-notes": "<p></p>" }, "Synthetic peptide": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "IHC-species-checked": "notRecommended", "IHC-species-dilution-info": "", "IHC-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Species reactivity
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species.
Please contact us for more information.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

EGFR or Epidermal Growth Factor Receptor is a transmembrane glycoprotein that acts as a receptor for members of the epidermal growth factor family. Known alternatively as ErbB1 or HER1 this receptor has an approximate molecular weight of 170 kDa. EGFR is expressed in various cell types notably on epithelial cells and can influence multiple cellular processes through its kinase activity. It participates in the regulation of cell growth multiplication and survival by activating its kinase domain upon ligand binding.
Biological function summary

The EGFR protein plays an important role in cellular communication and signaling processes. EGFR pairs with other receptor family members to form active dimers or even higher-order complexes which in turn initiate intracellular signaling cascades. Through these complexes EGFR influences many processes including cell differentiation and repair. This function of EGFR makes it an integral part of mammalian biology affecting how cells respond to their environment by mediating changes in gene expression.

Pathways

EGFR is a central player in the MAPK and PI3K/Akt signaling pathways. Alongside other protein partners like KRAS and PI3 kinase it contributes to transmitting signals from the cell surface to the nucleus affecting gene transcription and cell behavior. These pathways are important for normal cell growth and division and aberrations in these pathways can lead to excessive or insufficient cell proliferation.

EGFR is pertinent to cancer biology including non-small cell lung cancer and glioblastoma where mutations or overexpression of the receptor frequently occur. It connects to proteins such as PTEN and BRAF which influence tumor progression and response to targeted therapies. EGFR's involvement in these disorders highlights its significance as a therapeutic target since it can be manipulated to alter disease progression.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed : 10805725, PubMed : 27153536, PubMed : 2790960, PubMed : 35538033). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed : 12297049, PubMed : 15611079, PubMed : 17909029, PubMed : 20837704, PubMed : 27153536, PubMed : 2790960, PubMed : 7679104, PubMed : 8144591, PubMed : 9419975). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed : 27153536). May also activate the NF-kappa-B signaling cascade (PubMed : 11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed : 11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed : 11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed : 20462955). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity).. Isoform 2 may act as an antagonist of EGF action.. (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.
See full target information EGFR phospho Y1086

文献 (12)

Recent publications for all applications. Explore the full list and refine your search

Cell communication and signaling : CCS 22:140 PubMed38378560

2024

Crosstalk between KDEL receptor and EGF receptor mediates cell proliferation and migration via STAT3 signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Jie Jia,Lianhui Zhu,Xihua Yue,Shuocheng Tang,Shuaiyang Jing,Chuanting Tan,Yulei Du,Jingkai Gao,Intaek Lee,Yi Qian

Cell cycle (Georgetown, Tex.) 21:1726-1739 PubMed35499499

2022

Beta-carotene regulates the biological activity of EGF in IEC6 cells by alleviating the inflammatory process.

Applications

Unspecified application

Species

Unspecified reactive species

Wang Guoxia,Yang Yu,Zhang Shuai,Lan Hainan,Xin Zheng

Journal of cell science 131: PubMed29669739

2018

Tissue stiffening promotes keratinocyte proliferation through activation of epidermal growth factor signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Fiona N Kenny,Zoe Drymoussi,Robin Delaine-Smith,Alexander P Kao,Ana C Laly,Martin M Knight,Michael P Philpott,John T Connelly

Scientific reports 7:9995 PubMed28855649

2017

Dysfunction of the circadian transcriptional factor CLOCK in mice resists chemical carcinogen-induced tumorigenesis.

Applications

Unspecified application

Species

Unspecified reactive species

Ken-Ichi Hashikawa,Chiharu Katamune,Naoki Kusunose,Naoya Matsunaga,Satoru Koyanagi,Shigehiro Ohdo

Cancer research 75:4937-48 PubMed26490646

2015

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Alexandra B Lantermann,Dongshu Chen,Kaitlin McCutcheon,Greg Hoffman,Elizabeth Frias,David Ruddy,Daniel Rakiec,Joshua Korn,Gregory McAllister,Frank Stegmeier,Matthew J Meyer,Sreenath V Sharma

Cancer chemotherapy and pharmacology 75:837-50 PubMed25702049

2015

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Applications

WB

Species

Unspecified reactive species

Georgina Meneses-Lorente,Thomas Friess,Irene Kolm,Gabriele Hölzlwimmer,Sabine Bader,Christophe Meille,Marlene Thomas,Birgit Bossenmaier

International journal of clinical and experimental 6:1493-504 PubMed23923067

2013

RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.

Applications

WB

Species

Human

Zhi-Hong Xu,Jun-Biao Hang,Jia-An Hu,Bei-Li Gao

Neuro-oncology 15:1200-11 PubMed23723255

2013

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.

Applications

WB

Species

Human

Mikael Johansson,Anaïs Oudin,Katja Tiemann,Amandine Bernard,Anna Golebiewska,Olivier Keunen,Fred Fack,Daniel Stieber,Baofeng Wang,Håkan Hedman,Simone P Niclou

Protein engineering, design & selection : PEDS 25:551-9 PubMed22936109

2012

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.

Applications

WB

Species

Human

R Castoldi,U Jucknischke,L P Pradel,E Arnold,C Klein,S Scheiblich,G Niederfellner,C Sustmann

PloS one 7:e41179 PubMed22815959

2012

Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.

Applications

WB

Species

Unspecified reactive species

Anke Bill,Anton Schmitz,Katharina König,Lukas C Heukamp,Jeffrey S Hannam,Michael Famulok
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com